Search results (86)
« Back to NewsOxford and Liverpool scientists launch new vaccine trial for Middle East Respiratory Syndrome (MERS)
19 September 2023
Clinical Trials General Research
The UK trial is the next step in the development of a vaccine to protect people against MERS – a deadly viral illness with no current vaccines and the potential to cause a pandemic.
First volunteers receive vaccine for Crimean-Congo haemorrhagic fever in Oxford clinical trial
13 September 2023
Clinical Trials General Research
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. Launched on the 4th of August 2023, the clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
Oxford to launch UK’s first trials unit dedicated to precision-prevention and early detection studies
18 July 2023
Clinical Trials General Research
Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
African Phase I HIV vaccine trial shows encouraging preliminary results
12 July 2023
Clinical Trials General Research
The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully.
Drug shows promise for stroke patients with bleeding in brain
4 July 2023
Clinical Trials General Research
A clinical trial has shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side effects of blood-thinning drugs for patients who have experienced a stroke.
Rapid weight loss found to be safe and helpful for people with liver disease, Oxford trial reveals
28 June 2023
Clinical Trials General Research
A clinical trial, led by a team at NDPCHS, has shown that a three-month rapid weight loss programme was not only safe but also effective in reducing the severity of a liver disease called non-alcoholic steatohepatitis (NASH) with liver fibrosis.
Major trials to test effectiveness of cannabidiol on psychosis
16 February 2023
Awards and Appointments Clinical Trials General Research
A global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.
Oxford spinout trials revolutionary bioelectronic implant to treat incontinence
1 February 2023
Clinical Trials General Innovation Research
The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.
Molnupiravir doesn't reduce COVID-19 hospitalisations in high-risk vaccinated people
3 January 2023
Clinical Trials General Research
Researchers from the University of Oxford released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial. In their paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community.
Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak
18 November 2022
Clinical Trials General Research
A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from the Jenner Institute (Nuffield Department of Medicine) has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.
New study shows muscle pain is not due to statins in over 90% of those taking the treatment
30 August 2022
Clinical Trials General Research
Statin therapies are not the cause of muscle pain in over 90% of those who experience symptoms, according to a new study led by researchers from Oxford Population Health. The results were published today in The Lancet and presented at the European Society of Cardiology Congress.
Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination
29 June 2022
Clinical Trials Coronavirus COVID-19 General Research
The Oxford Clinical Trials Research Unit at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) played a key role in the Vaccine Response On Off Methotrexate (VROOM) study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.
Breakthrough in treatment for Dupuytren’s disease
30 April 2022
Clinical Trials General Research
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.
World Malaria Day 2022
25 April 2022
Clinical Trials General Research
Patient recruitment is on-track in the Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa.
RECOVERY Trial launches in South Africa
13 December 2021
Clinical Trials Coronavirus COVID-19 General
The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.
Ebola vaccine to begin human trials
11 November 2021
Clinical Trials General Research
The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.
Oxford researchers test potential treatment for fatigue in long COVID patients
29 October 2021
Clinical Trials Coronavirus COVID-19 General Research
Radcliffe Department of Medicine researcher Dr Betty Raman is leading a new phase 2a clinical trial to investigate whether a drug could treat the fatigue and muscle weakness experienced by many patients who have recovered from COVID. The drug, AXA1125, is developed by the US-based biotechnology company Axcella Therapeutics.
Anti-cancer drug derived from fungus shows promise in clinical trials
7 October 2021
Clinical Trials General Innovation Research
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
African trial of novel HIV vaccine candidate starts
4 August 2021
Clinical Trials General Research
The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) – of which the University of Oxford is a lead partner – announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.
Phase I trial begins of new vaccine against the Plague
27 July 2021
Clinical Trials General Research
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.